APL-1501
Urological Tumors
Not SpecifiedActive
Key Facts
About Asieris Pharmaceuticals
Founded in 2010 and publicly listed in China (688176.SH), Asieris Pharmaceuticals is a global biopharma leader in genitourinary and women's health. Its strategy integrates in-house R&D with global partnerships, supported by advanced technology platforms for drug discovery. The company has achieved significant milestones, including the approval of its first-in-class therapy Cevira® in China and the submission of a Marketing Authorization Application to the European Medicines Agency.
View full company profileTherapeutic Areas
Other Urological Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| AT-014 | Asieris Pharmaceuticals | Not Specified |